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Platinum compounds are widely used drugs in cancer treatments. Although DNA 
is the biological target, reaction of platinum compounds with proteins is also potentially 
significant. Our objective is to study the effects of leaving ligands on the relative 
reactivity between 5'-GMP (guanosine 5' phosphate), a key DNA target, and N-Acetyl -
L-Methionine (N-AcMet), a key protein target. We have used NMR spectroscopy to 
monitor reactions with N-AcMet and 5'-GMP added to a platinum complex to see which 
products are formed preferentially. Previous research showed that both a non-bulky 
complex such as [Pt(en)(D2O)2]2+  [en=ethylenediamine], and a bulky complex such as 
[Pt(Me4en)(D2O)2]2+ [Me4en= N, N, N', N'-tetramethylethylenediamine] react more 
quickly with 5'-GMP than with N-AcMet. To improve the activity of platinum 
compounds in our current research, oxalates as leaving ligands are used. The results 
suggest that [Pt(en)(Ox)] [Ox= oxalate] reacts faster with N-AcMet  than with 5'-GMP. 
Also, [Pt(Me4en)(Ox)] reacts slowly with 5'-GMP without N-AcMet and the reaction 
favors N-AcMet when both ligands are added simultaneously. Interestingly, the 
formation of the sulfur-oxygen chelate is slow enough to be observable in the oxalate 
reaction; but the mono product is not independently observed in the dinitrate complex. 
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I. INTRODUCTION 
 
 A. History 
Cancer is a term used for diseases in which abnormal cells divide without control 
and are able to invade other tissues. Cancer cells can spread to other parts of the body 
through the blood and lymph systems. There are over 200 different known cancers that 
effect humans. Many things may elevate the risk of cancer, including external factors 
such as chemicals, radiation, environmental pollutants as well as internal factors like 
mutations, hormones, and immune system conditions. Genetics account for 
approximately 5-10% of cancers. The current treatment options are surgery, radiation, 
chemotherapy, hormone therapy, biological therapy, and targeted therapy.1  
The anticancer activity of cisplatin [PtCl2 (NH3)2] was first discovered by Barnett 
Rosenberg in 1960. It is estimated that about 90% of testicular cancers are cured by 
cisplatin and considered to play vital roles in treatment of ovarian, neck, bladder, and 
cervical cancers.2 The clinical success of this drug initiated the use of metal compounds 
for cancer.1 Following this, preparation and evaluation of thousands of platinum 
compounds was started by scientists. However, only a few compounds have actually 
entered into clinical use.1 Carboplatin {cis-(Pt(NH3)2(CBDCA)],CBDCA= 1,1-
cyclobutanedicarboxylic acid} and oxaliplatin {[Pt(oxalate)(1R,2R-chxn)], chxn= 
cyclohexane-1,2-diamine} were a few of the drugs that were discovered, found to display 
anticancer activity complementary to cisplatin.  
The anticancer activity of platinum compounds were first investigated by 
Rosenberg while he was studying electric field effects on bacterial growth. The 
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electrodes that were made of platinum electrolyzed during the experiment and released a 
platinum complex that caused inhibition of cell division in the bacterial rods. This 
experiment was first carried out in Escherichia coli (E. coli) using ammonium chloride 
buffer as an growth medium. Current was passed through inert platinum electrodes 
immersed in the buffer.3,4 The result was that the E. coli cells began appearing long and  
filamentous, similar to spaghetti, instead of their original sausage shape.4 From the 
filamentation assay, the scientists hypothesized that the charged platinum complexes 
were bactericidal and that this inhibition of cell division was not due to the electrical 
current. It instead was due to the platinum hydrolysis products formed from the platinum 
electrodes.3 Rosenberg also reported that the cis form of platinum (IV) complex 
[PtCl4(NH3)2] was responsible for inhibition, whereas the trans form is ineffective. An 
experiment was also carried out on swiss white mice injected with cis-[Pt(Cl4(NH3)2], a 
platinum (IV) complex, and a platinum(II) complex cis-[Pt(Cl2(NH3)2]; the result was 
that the large solid tumors in the mice were reduced in size and the mice survived.3,4  The 
first clinical trials in 1972 gave very promising results. The experiments established 
cisplatin’s efficacy as an anticancer drug, and the final approval of this drug in the United 
States was in 1979. Since then, it has become one of the leading and most widely used 
anticancer drugs. Better knowledge of the mechanism may lead to better administration 
procedures and derivatives or analogues with superior properties.3 
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Figure 1. Structure of Cisplatin 
B. Synthesis of Cisplatin 
 The synthesis of cisplatin was carried out in 1845 by Michel Peyrone.1 Initially 
the synthesis of cisplatin was unreliable, often producing impure products. Alterations 
were made for improved purity of the product.1,4,5 The synthetic procedure of cisplatin is 
explained in a schematic diagram in Fig 2. First, it involves potassium 
tetrachloroplatinate (K2[PtCl4]) which is then converted to the tetraiodo analog K2[PtI4] 
by the addition of potassium iodide (KI). The ammonia is added, forming a yellow 
compound that is dried. After that, addition of an aqueous solution of  silver nitrate 
(AgNO3) to cis-[PtI2(NH3)2] causes insoluble AgI to precipitate. This is then filtered off. 
Finally potassium chloride (KCl) is added to attain product of cisplatin cis-
[PtCl2(NH3)2].1,4 
                                    
Figure 
 
 
C. Rate of Ligand-Exchange R
Ligand-exchange kinetics play a
activity.6,7 The platinum ligand bond, having
coordination bond, is weaker than C
ligand- exchange behavior provides a reaction
reaches the target site despite various competing interactions
reactions on platinum occur faster than 
reaction velocities of platinum compounds. This concept 
Chernyaev in the year 1926
certain ligand in a platinum
to others. This results in sequences of reactivity.
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2. Synthetic pathway of Cisplatin 
eactions of Platinum Compounds  
n important role in determining the anticancer 
 thermodynamic strength of a typical 
-C, C-N or C-O, single, and double bonds. The 
 from minutes to days to allow to reach
. Certain ligand
others. 3 The trans-effect determine
was first introduced by 
.
1 It states that, ligands in positions opposite (trans) to a 
(II) compound are more or less rapidly exchang
 For example, ligands trans to 
 
 
-exchange 
s the relative 
ed compared 
the 
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following compounds in the sequence are more easily replaced: CN->phosphine>NO2->I-
>Br->CI->NH3>H2O.1,3,4  
 When the intermediate triiodo species K[PtI3(NH3)] reacts with the second 
ammonia group there are two options as illustrated in Fig. 2, they are either displacement 
of the iodo ligand that is trans to an ammonia ligand or displacement of the iodo ligand 
that is trans to another iodo ligand. With an increase of the trans directing influence of 
iodo ligand relative to ammonia ligand, the ligand trans to iodide is labile and can be 
easily displaced to give cis configuration of the final product.1 Therefore ligands, in the 
platinum compounds, determine the reactivity. In addition to the trans effect rule, Pt-
amine ligand bonds such as Pt(NH3)2+2 are usually very stable and Pt-H2O bonds and Pt-
Cl bonds are labile.3 Based on this concept, different platinum compounds are 
synthesized by modifying their ligands to change their reactivity.3,4  
D. Structure and Activity Relationship  
Although cisplatin has clinical success, there are side-effects associated with the 
cisplatin treatment such as nephrotoxicity, nausea, ototoxicity, and severe anemia.1,6 For a 
drug to gain clinical approval it needs to have at least one unique clinical advantage over 
cisplatin, such as reduced toxic side-effects. There are certain structural criteria for the 
platinum compounds to show the antitumor activity (i.e. there is a relationship between 
structure and activity).1 
• It is necessary that the compound should have two leaving groups that are cis with 
respect to each another. 8,9 Leaving groups are those that are most easily lost. The 
ease with which these leaving groups are lost will affect the activity as well as 
toxicity of the compound. 8, 9 
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• The compound should be neutral with fewer alkyl substituents on the amine 
ligands.1 
• The two amine groups should have cis geometry. The trans geometry will make 
these compounds inactive for antitumor activity.1,3 
• Two cis-monodentate or one bidentate leaving group is required.9 
• The geometry of the complexes is either square planar or octahedral.9 
• The complexes should have at least one N-H group, which is required for 
hydrogen bonding with the biological target.3,9 
• The leaving groups must be approximately 3.4 Å apart on the molecule.9 
• The rates of exchange of these groups should fall into restricted region. 
 
 
Figure 3. General Structure of Platinum Compounds with Anti-Tumor Activity 
  X is the leaving group such as two chloro groups or a bidentate malonate ligand; 
R=H or an alkyl substituent. (Fig.3)  
The majority of the platinum compounds that are clinically successful have 
adhered to this structure and activity criteria.1  Based on these structure activity 
relationship, other platinum compounds with improved efficacy and less toxicity are 
designed. Second and third generation platinum drugs such as carboplatin and oxaliplatin, 
respectively to overcome cisplatin resistance have been introduced.  
 E. Analogs of Cisplatin 
  Carboplatin: Introduced in the year 1980,
platinum drug with lesser side
combination therapy.6 It is also called cis
platinum(II) and is mainly used in ovarian carcinoma, lung, head and neck cancer
The cyclobutanedic
leaving group of cisplatin
compared to cisplatin as the rate of conversion to active species is slowed down
drugs bond with the thiol sulfur
difference between cisplatin and carboplatin is that the carboplatin is a bigger molecule 
with a dicarboxylate ligand which reduces the breakdown of agent metabolically and 
lowers the formation of toxic by
to the kidneys and nervous system than cisplatin and caused less nausea and vomiting 
retaining equivalent anti-tumor activity.
 Oxaliplatin: Oxaliplatin 
diaminocyclohexane (dach) carrier ligand and an oxalate leaving group.
trans-R, R-1, 2-diaminocyclohexane oxalate platinum(II), it has 
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 carboplatin is the second generation 
-effects when compared to cisplatin; it is used in 
-diammine (1.1-cyclobutanedicarboxylato)
arboxylate (CBDCA) ring on carboplatin replaces the chl
. This replacement reduces the toxicity of carboplatin when 
 atoms of proteins and amino groups in DN
products. Carboplatin is considered markedly less toxic 
12
 
 
 
Figure 4. Structure of Carboplatin 
is a third generation platinum anticancer drug with a 
11
decreased resistance in 
 
.
10-12
 
oride 
.
1,6
 These 
A. The only 
 Known also as 
 cisplatin-resistant tumors. Oxaliplatin is the FDA approved drug 
treating colorectal cancer
the differences in cellular activity may be due to the differential recognit
adducts. These differences 
the similar type of inter and 1
spectrum of activity, mechanisms of a
carboplatin. However, the steric 
platinum adduct results in absence of cross resistance with cisplatin and carboplatin.
main side-effects of this drug are neurotoxicity, hematological toxicity, gastrointestinal 
tract toxicity, and tubular necrosis.
 
F.  Hydrolysis Reactions of Cisplatin
 After administration of the 
blood stream, a variety of chemical reactions 
(100 mM) suppresses hydrolysis to maintain the cisplatin
cisplatin that remains intact 
membrane. With intracellular chloride concentration in the bloo
low (i.e. 4-20 mM), a chloro ligands of 
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with greater efficacy in 
.
 Although it has similar DNA binding specificity to cisplatin, 
ion of DNA 
may be due to the differences in uptake. Oxaliplatin  produces 
,2-GG intrastrand cross links as cisplatin, but has
ctions, and resistance than cisplatin and 
characteristics of non-hydrolysable diaminocyclohexane 
12
 
 
 
Figure 5. Structure of Oxaliplatin 
 
cisplatin drug through injection or infusion in the 
occur. A high concentration of chloride ions 
 in a neutral state.
enters the tumor cells by diffusing through the cell 
d plasma being 
cisplatin is replaced by water  to form a reactive, 
 a different 
 The 
13 The 
relatively 
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positively charged species that cannot readily leave the cell.13  The aqua ligand in cis 
[PtCl(H2O)(NH3)2]+  is easily displaced. This allows the platinum atoms to bind to all 
kinds of molecules inside the cell like DNA, RNA, proteins.3 In vitro, studies have shown 
that this monoaquated platinum species is responsible for at least 98 percentage of 
platinum binding to DNA within the cell nucleus.1 Of the DNA bases, guanine is the most 
preferred.14 
It is generally accepted that chloride hydrolysis is considered  as a rate 
determining step in the reaction of cisplatin with DNA.4 Significant losses of platinum  
occur due to 50-70% of the administered platinum being excreted within 24 hours.4  
 
 
 
            Figure 6. Hydrolysis Reactions of Cisplatin 
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G.  Mechanism of Action of Platinum Anti-Tumor Drugs 
                                               
 
 
Figure 7. Guanine Residues of DNA 
 
DNA as the Target                            
Specific interaction of cisplatin with DNA causes cell death.4 Aquated form of 
cisplatin is considered more reactive than neutral cisplatin. Earlier studies have shown 
that cisplatin preferentially binds at the nitrogen atoms of the nucleobases.4 To understand 
this, studies have been conducted on binding preferences of nucleobases adenine (A), 
guanine (G), and cytidine (C). In guanine, binding is possible at N7 and deprotonated N1 
under alkaline conditions. Of all these binding modes those at N7 atoms of adenine and 
guanine seem most compatible to DNA. This is thought to happen because the other sites 
of A, G, and C are involved in the Watson-Crick base pairing of double helix.4 The 
kinetic and competition studies conducted a decade ago have shown that guanine N7 has 
a strong kinetic preference. Recent investigations have shown a Pt-N7 guanine bond is   
NH
NNH
N
O
NH2
  
11 
stable.3,4  The cis-Pt unit has two reactive sites and after binding to one guanine N7
 
 a 
second reaction with a nearby guanine can occur.4 
 
Figure 8. Cisplatin Interaction with DNA 
 In carboplatin and oxaliplatin, the interactions with DNA occur at the position 
where cyclobutane-1, 1-dicarboxylate (CBDCA) and oxalate ligands are attached to 
platinum.15,16  This binding leads to a distortion of double helical structure of DNA thus 
impairing its processing. The 1, 2 intra strand cross-links bend the DNA towards the 
major groove exposing it to a wide shallow minor groove surface to which several 
proteins bind. High mobility group proteins, or the HMG proteins, are the proteins which 
are bound and cause cell cycle arrest, cell death, replication inhibition, and transcription 
inhibition.13    
 
 
Figure 9. Guanosine 5'-Monophosphate 
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 H. Preference of Platinum(II) Complexes for Guanine over Adenine                    
Previous results from the experimental observations suggest that the guanine is 
the preferred reactant for platination.17 The N7 platination of guanine is both 
thermodynamically and kinetically more favorable. A strong hydrogen bond between the 
hydrogen of ammine ligand on platinum and the oxo group at C6 position of guanine 
stabilize the platinum-guanine adduct. In comparison to the platinum-adenine adduct, this   
results in 50% of the differential energy when the Pt-chloroaqua complex is the reactant.   
The Pt-adenine adduct serves as the hydrogen bond donor and is energetically 
unfavorable compared to an isomer where the amino functionality on the C6 position acts 
as hydrogen donor to the chlorine ligand. If the diaqua complex is used as platination 
agent, both the kinetic and thermodynamic preferences for guanine are increased 
dramatically to 9.6 and 7.4 Kcal/mol respectively.17 Therefore guanine is preferred with 
higher selectivity if diaqua complex is the active platinum (II) complex to bind. 
I. Reaction of Platinum Complexes with Proteins                
DNA is not the only target for platinum complexes; binding to proteins also 
occurs.3 Studies have shown that one day after cisplatin administration, 65 to 98% of the 
platinum in blood plasma is protein bound and significant protein adducts are formed.18,19 
The reaction of platinum complexes with proteins results in formation of protein adducts, 
which may be responsible for side-effects and drug resistance. In amino acids, sulfur 
donor residues (Cysteine, Methionine) are primary targets owing to the relative softness 
of platinum.21 Platinum also binds to the lone pairs of nitrogen atoms which occur in 
amino acids in the absence of S-donor ligands.20 
 Due to cisplatin’s affinity for sulfur ligands,
cysteine and methionine residues is 
N-Acetyl –L-Methionine 
representative of internal methionine residue in peptide or protein to study the reactivity 
of platinum complexes.21
intramolecular competition reactions to verify the binding preference of platinum in 
presence of both sulfur grou
platinum reaction with methionine and related ligands is kinetically fav
reaction of platinum with guanine is thermodynamically favored.
reactivity with platinum complexes may act as a reservoir for platinum to form act
intermediates which result 
important to better understand the interaction of platinum complexes with DNA and 
proteins and to determine what factors affect the rates of reaction.
Figure 10. 
 Previous studies were focused on [Pt(Me
tetramethylethylenediamine) as a bulky platinum 
(en=ethylenediamine) a less bulky ligand
cisplatin and carboplatin. NMR spectroscopy 
5'-GMP are added to platinum complexes at pH 4. It was analyzed from the studie
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 reaction with peptides and proteins at 
common.18 Many studies have utilized the amino acid 
(N-AcMet), which has an amide nitrogen and is the 
-22
 Research has been conducted to study the int
ps and N7 atoms of nucleobases.23-25 It was shown that 
ored whereas the 
18,24,25 Sulfur group 
in platination of N7 position of DNA.9 It is, therefore
18
 
 
Structure of N-Acetyl-L-Methionine (N-AcMet)
4en)(D2O)2]+2  (Me4en=N,
diamine complex. [Pt(en)(D
, was used to represent the diamine ligands of 
monitored reactions where 
ermolecular and 
ive 
, 
 
 N, N', N'-
2O)2]+2 
N-AcMet and 
s that 
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the [Pt(en)(D2O)2]+2  reacts more quickly than [Pt(Me4en)(D2O)2]+2  as expected.18 
Although both complexes showed good reactivity with 5'-GMP, [Pt(en)(D2O)2]+2  
complex favors reaction with 5'-GMP because of hydrogen bonding of the en ligand with 
the 5'-phosphate. In contrast, reactivity of [Pt(Me4en)(D2O)2]+2 is disfavored with N-
AcMet due to steric clashes.16 Because the bulk had little effect on N-AcHis (N-
Acetylhistidine), His residues may be favored reaction over methionine residues in 
protein reactions18 
Present research focuses on modifying the platinum(II) complexes with oxalates 
as a leaving groups and ethylenediamine as ligands. [Pt(en)(Ox)] represents a less bulkier 
complex where as [Pt(Me4en)(Ox)] is used as bulkier complex. Both compounds feature 
a square planar coordination complex and are classified as alkylating agents and a 
coordination complex. 
Oxalates are mainly preferred as they are very good water soluble leaving ligands 
and are used by oxaliplatin. The features for the bidentate ligand, ethylenediamine, would 
be less steric bulk and symmentry with two monodentate ammine ligands of cisplatin.  
Proton NMR spectroscopy has been utilized to monitor the competition reactions 
in which N-Acetyl-L-Methionine (N-AcMet) and Guanosine-5'-mono-phosphate (5'-
GMP) are added to platinum complexes to see which products are formed at pH-4. 
Different ratios of 5'-GMP and N-AcMet are reacted with platinum to maintain the 
constant ratio of platinum (II) complexes at pH 4. 
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II. MATERIALS AND METHODS 
A. Materials Used 
 
 The following items were purchased from Sigma Aldrich: Potassium 
tetrachloroplatinate (II) (K2PtCl4), silver nitrate (AgNO3), dichloro (ethylenediamine) 
platinum(II) (H2NCH2CH2CH2NH2)PtCl2), deuterium oxide (D2O), N-Acetyl -L- 
Methionine (N-AcMet), (CH3SCH2CH2CH(NHCOCH3)CO2H),  guanosine 5'- mono-
phosphate dehydrate (5'-GMP), (C10H14N5 O8P), oxalic acid (anhydrous) (C2H2O4), silver 
oxalate (Ag2C2O4). 
B. Nuclear Magnetic Resonance Spectroscopy (NMR) 
 A JEOL Eclipse 500 MHz Nuclear Magnetic Resonance spectrometer was 
utilized. 1H NMR spectroscopy was used to characterize the products and to analyze the 
rate of the product formation. 
C. Synthesis of [Pt(Me4en)(Ox)] 
 In this synthesis, 83 mg of potassium tetrachloroplatinate(II) (98%) is added to 
 5 mL of water in a round bottom flask. 30 µL of N, N, N', N '-
tetramethylethylenediamine and 5 mL of methanol were combined in a beaker. This 
mixture is added drop-wise to the potassium tetrachloroplatinate mixture, and allowed to 
stir for 24 hours. The obtained solid is collected through gravity filtration and then dried.   
Preparation of Silver Oxalate  
A sample of 450 mg of oxalic acid and 1690 mg of silver nitrate are added in an 
amber vial. A 20 mL deionized water was added and allowed to stir for one hour. The 
insoluble silver oxalate was collected by vacuum filtration. 
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The Final Step in the Synthesis of [Pt(Me4en)(Ox)] 
Silver oxalate is combined with the dried product in an equal molar ratio in ~30 
mL of water and stirred overnight.  After this, the mixture is syringe filtered to remove 
the silver chloride. The aqueous solution is evaporated to dryness to obtain the product. 
Weight of silver oxalate to be added = 
Obtained product of N, N, N, N tetramethylethylenediamine×Mass of silver Oxalate 
Weight of Pt(Me4en)Cl2  
D. Second Synthetic Method for Preparation of [Pt(Me4en)(Ox)] 
56.5 mg of Pt(Me4en)I2 and 30 mg of silver oxalate is added to 30 ml of deionized 
water. The product was dried in a rotovap to obtain [Pt(Me4en)(Ox)]. 
E. Synthesis of [Pt(en)(Ox)]  
65.2 mg of platinum(II) ethylenediamine dichloride and 60 mg of silver oxalate 
are added to 35 mL of water and allowed to stir for 24 hours. The product was gravity 
filtered to remove any excess silver oxalate and dried in a rotovap to obtain [Pt(en)(Ox)]. 
F. Reactivity of [Pt(en)(Ox)] with 5'- GMP and N-AcMet 
 The reaction between the water soluble platinum compound [Pt(en)(Ox)], N-
AcMet and 5'-GMP  was monitored at mole ratios of 1:1, 1:2 individually and 
competitively at mole ratios of 1:2:1 and 1:4:1. Additionally 1.5 mL of D2O was added to 
the amber vial. After keeping the pH around 4-5, the solution was transferred to an NMR 
tube for NMR spectroscopy. 
  
17 
G. Reactivity of [Pt(Me4en)(Ox)] with 5'- GMP and N-AcMet 
The reaction between [Pt(Me4en)(Ox)], 5'-GMP and  N-AcMet was followed at 
mole ratios of 1:1, 1:2 individually and competitively at mole ratios of 1:2:1 and 1:1:2. 
After keeping the pH around 4-5, the solution was transferred to an NMR tube for NMR 
spectroscopy. 
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The 1:2 products formed from the reaction have key resonances at ~8.5 ppm. 
Each side of the NMR spectrum has the y-axis scaled to the largest peak to make the 
signals easier to observe. The product signals are indicated by an asterisk. 
 The 5'-GMP H8 signals shifted downfield at ~8.5 ppm indicates the coordination 
of the platinum complex with 5'-GMP via N7 atom of the guanine. The predominant  
bis-products are formed indicating the formation of the complex [Pt(en)(Ox)( 5'-GMP)2]. 
 For both the molar ratios of 1:1 and 1:2 the [Pt(en)(Ox)] reacts with 5'-GMP. The 
downfield chemical shift at ~8.5 ppm indicates the [Pt(en)(Ox)] reacts with 5'-GMP, 
resulting in the formation of bis-products with two 5'-GMP substituted in a platinum 
compound. 
C.  Reactivity of [Pt(en)(Ox)] with N-AcMet at 1:1 Ratio 
N-AcMet was initially chosen because it has been utilized in similar studies and 
because the methyl signal from the acetyl group provides another NMR signal that is 
readily observable. 10 mM [Pt(en)(Ox)] and10 mM N-AcMet at 1:1 molar ratio are 
combined. The pH is determined and adjusted to 4. The reaction was monitored at 
intervals 1 hour, 24 hours, and 48 hours. The signal at ~2.5 ppm is a typical chemical 
shift for the S-CH3 resonance of sulfur coordinated N-AcMet.26 The N-AcMet connects 
to the pt(en) via sulfur.  
Fig. 15 shows the 1H NMR spectrum of [Pt(en)(Ox)] and N-AcMet. The intensity 
of the signals corresponding to a chemical shift of ~2.2 ppm and ~2.5 ppm increased as 
the time of the reactivity increased. 
 
 
 Figure 15. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with 
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The signal at~ 2.2 ppm, ~2.5 ppm is a typical chemical shift for the S-CH3 
resonance of a sulfur coordinated N-AcMet.18,26 The signals from~ 2.1 ppm and ~2.3 ppm 
are from unreacted N-AcMet. The amount of unreacted N-AcMet decreases only slightly 
from 24 to 48 hours indicating the reaction between platinum and N-AcMet is mostly 
complete after 24 hours.  
Comparing the reactivity of  N-AcMet with [Pt(en)(Ox)] to the reactivity of 
[Pt(en)(Ox)] with 5'-GMP, the reaction of N-AcMet with [Pt(en)(Ox)] is faster and  
shows the reactivity at 1 hour and is mostly complete within 24 hours. The reactivity with 
5'-GMP is only partially complete after 24 hours. The results from Kung et al., indicated 
a competitive situation between 5'-GMP and L-Methionine for coordinating oxaliplatin 
and a favored coordination of L-Methionine.27 Consistent with the current study, 
[Pt(en)(Ox)] reactivity with N-AcMet is faster when compared to the reactivity with 5'-
GMP. The oxalates are easily displaced with that of methionine residues and thus product 
formation was observed quickly in hours rather than days as in the case of reaction of 
[Pt(en)(Ox)]with 5'-GMP.  
D. Reactivity of [Pt(en)(Ox)] with N-AcMet at 1:2 Ratio 
 
10 mM [Pt(en)(Ox)] and 20 mM  N-AcMet  at 1:2 molar ratio were reacted at pH 
4. The reaction was monitored at 1 hour, 24 hours, and 48 hours. The signals at ~2.2 ppm 
and ~2.5 ppm are typical chemical shifts for the S-CH3 resonance of a sulfur coordinated 
N-AcMet.26 The N-AcMet connects to the pt(en) via sulfur.  
Fig. 16 shows the partial 1H NMR spectrum of 10 mM of [Pt(en)(Ox)] and 20 
mM of N-AcMet at pH 4.0 after 1 hour and 24 hours. The products formed from the 
reaction with [Pt(en)(Ox)] and N-AcMet has key resonances at ~2.2 ppm and ~2.5 ppm 
 indicating the sulfur of methionine coordination with [Pt(en)(Ox)] and thus formation of 
products.  
 
 
 
 
 
Figure 16. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with 
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The products formed from the reaction with 5'-GMP and N-AcMet have key 
resonances at ~8.6 ppm and ~ 2.5 ppm respectively. (Fig.19).  
The reactivity of [Pt(en)(Ox)] with 5'-GMP was  slow after 24 hours and 
remained similar in its intensity even after 48 hours. Product signals at ~8.6 ppm were 
observed corresponding to [Pt(en)(N-AcMet-S)(5'-GMP-N7)] which indicates  the 
reaction of the platinum complex with guanine via N7 residues at 24 hour time. There 
was significant amount of product formed for N-AcMet initially after 24 hours and 
increased dramatically even after 48 hours. Also, there were more intense peaks observed 
at ~2.5 ppm indicating the downfield shift of methionine with [Pt(en)(Ox)] at 48 hours. 
The S-CH3 signal of [Pt(en)(N-AcMet-S)] occurs at ~2.5 ppm. As Fig. 19 indicates, more 
products are initially formed with N-AcMet than with 5'-GMP. Throughout the reaction, 
the amount of N-AcMet reacted exceeds the amount of 5'-GMP reacted. Within ~48 
hours, signals due to [Pt(en)(N-AcMet-S)2] were observed. On the basis of previous 
results,18,26  the final product from the studies are [Pt(en)(N-AcMet-S)(5'-GMP-N7)]  and 
a bis coordinated N-AcMet product [Pt(en)(N-AcMet-S)2]. Compared to the previous 
results,18  the [Pt(en)(ox)] reacted quickly with N-AcMet than 5'-GMP.  
F. Reactivity of [Pt(en)(Ox)] with 5'-GMP and N-AcMet at 1:4:1 Ratio 
We modified the reactivity by adding 10 mM of [Pt(en)(Ox)] to  40 mM 5'-GMP 
and 10 mM N-AcMet. 500 µl aliquots of each were mixed together and the pH was 
determined. The reactivity is interpreted by 1H NMR spectra after 24 hours and 48 hours. 
(Fig. 20). 
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basis of the previous results,18,26 the products’ peaks can be interpreted. The intensity of 
signals for N-AcMet increased from a 24 hour time period to a 72 hour time period. The 
downfield shift of H8 signals at ~2.5 ppm corresponds to the N-AcMet bis-product 
[Pt(en)(N-AcMet-S)2], which is due to a sulfur coordination with methionine. There are 
also two products in the GMP range. At least one of the products that is left is due to 
[Pt(en)(N-AcMet-S)(5'-GMP-N7)], whereas the other signal which corresponds to bis 5'-
GMP products on the right side is due to [Pt(en)(5'-GMP)2]. 
In comparison to the previous results,26 the products formed when four 
equivalents of 5'-GMP were added to  the one-to-one mixture of [Pt(en)(Ox)] and N-
AcMet are [Pt(en)(N-AcMet-S)2], [Pt(en)(N-AcMet-S)(5'-GMP-N7)] and [Pt(en)(5'-
GMP)2]. 
Bulky Compounds  
 The competition reactions between N-AcMet and 5'- GMP with [Pt(Me4en)(Ox)] 
are studied quantitatively using 1H NMR at pH 4 at varying concentrations. 
G.  Reactivity of [Pt(Me4en)(Ox)] with 5'- GMP at 1:1 Ratio 
 The reactivity of [Pt(Me4en)(Ox)] with 5'-GMP is studied by the 1H NMR 
spectroscopy. 500 µL aliquots of 10 mM of [Pt(Me4en)(Ox)] with 10 mM of 5'-GMP are 
combined together and pH is adjusted to 4. The reactivity is interpreted by 1H NMR 
spectra after 24 hours, 48 hours, and 72 hours respectively. 
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[Pt(Me4en)(D2O)]2  reacted with 5'-GMP results in two possible steps one is that the 
reaction of diaqua complexes with the first guanine ligand. The second is the reaction of 
the mono-product with a second guanine ligand.18 Here, in this reaction when oxalates as 
a leaving ligands for Pt(Me4en) are utilized only [Pt(Me4en)(5'-GMP)2] is observed. The 
reactivity of [Pt(Me4en)(Ox)] with 5'-GMP was comparatively slow when compared to 
[Pt(en)(Ox)]. The Me4en bulk slowed the reactivity with 5'-GMP and took days to 
complete the reaction. (Fig. 21), (Fig. 22). 
I. Reactivity of [Pt(Me4en)(Ox)] with N-AcMet at 1:2 Ratio  
 
  500 µL aliquots of 10 mM of [Pt(Me4en)(Ox)] with 20 mM of N-AcMet were 
combined together, and reacted at pH 4; the reactivity is interpreted by the 1H NMR 
spectra after 1 hour, 24 hours, and 48 hours respectively.  
  A signal at ~2.5 ppm was assigned to the S-CH3 signal. The downfield shift of S-
CH3 signals indicates the sulfur coordination with methionine. (Fig 24). On the basis of 
comparison of previous results,20,26  we assigned the new sets of resonances that appeared 
to be at ~2.5 ppm which corresponds to [Pt(Me4en)(N-AcMet-S)(ox-O)](mono 
coordinated) and a signal at ~2.6 ppm which corresponds to [Pt(Me4en)(N-AcMet-S, 
O)+](sulfur-oxygen chelate). 
Formation of the complex [Pt(Me4en)(N-AcMet-S, O)+] appeared to be 
significantly faster than the formation of 5'-GMP complex as evidenced by the extent of 
reaction of each at 24 hours. When N-AcMet is added to the bulky platinum complex the 
oxalates are easily displaced within 24 hours to 48 hours of reactivity. The N-AcMet 
product is formed at 1 hour and a significant increase in the intensity of product signals at 
48 hours was observed.  
  The following 1H 
AcMet 
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previous results,20,26  we assigned the new sets of resonances that appeared to be at ~2.5 
ppm which corresponds to  [Pt(Me4en)(N-AcMet-S)(ox-O)](mono-coordinated) and a 
signal at ~2.6 ppm corresponds to [Pt(Me4en)(N-AcMet-S, O)+](sulfur-oxygen chelate). 
The signals at ~2.0 ppm and ~2.1 ppm correspond to the unreacted N-AcMet. The 
intensity of product signals at ~2.5ppm for S-CH3 increases dramatically from 1 hour to 
48 hours. 
 
 
  
Figure 25. 1H NMR spectrum of reactivity of 
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[Pt(Me4en)(Ox)] with 5'-GMP at 1:1 ratio.
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product. 26 According to the previous studies conducted, the mixed ligand complexes 
would not have severe steric clashes.27 The intensity of product peaks increased as the 
time increased resulting in the predicted product formation at ~8.8 ppm corresponding to 
[Pt(Me4en)(N-AcMet)( 5'-GMP-N7)] but is not due to [Pt(Me4en)( 5'-GMP)2].27  The 
significant downfield shift of the H8 atom indicates N7 coordination of 5'-GMP. 
Likewise, the S-CH3 signal at ~2.4 ppm which corresponds to [Pt(Me4en)(Ox)(N-AcMet-
S, O)]+.  The 1H NMR signals did not disappear even after several days and [Pt(Me4en)( 
5'-GMP)2] signals appeared, indicating complete displacement of N-AcMet did not occur. 
L. Reactivity of [Pt(Me4 en)(Ox)] with  5'-GMP and N-AcMet at 1:1:2 Ratio 
We modified the reactivity by adding one equivalent of [Pt(Me4en)(Ox)] with one 
equivalent of N-AcMet and 2 equivalent of 5'-GMP. After 24 hours, new signals were 
observed in the NMR spectrum. A new resonance in the H8 region of the spectrum was 
observed at ~8.8 ppm suggesting it is due to [Pt(Me4en) (N-AcMet)( 5'-GMP)]+. The 
significant downfield shift of the H8 atom indicates N7 coordination of 5'-GMP. 
Likewise, the S-CH3 signals at ~2.4 ppm corresponds to [Pt(Me4en) (N-AcMet-S, O)+2]. 
The 1H NMR signals did not disappear even after several days and no 
[Pt(Me4en)(5’GMP)2] signals appeared indicating the complete displacement of N-AcMet 
did not occur. 
 Figure 27. 1H NMR spectrum of reactivity of 
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IV. DISCUSSION 
In the current research the main focus is to check the reactivity of platinum 
complexes with guanine residues of DNA and methionine residues of proteins. Although 
the reaction with DNA is thought to be responsible for the anticancer activity, the 
reaction of platinum complexes with proteins is significant. It is suggested that protein 
binding contributes to the toxicity of platinum anticancer drugs; however, the reactivity 
of platinum with biological thiols may be a pathway for detoxification and resistance.26 
Therefore, better understanding of the interactions of platinum complexes with DNA and 
protein targets is important. With platinum being a soft metal, the sulfur atoms of 
methionine and cysteine residues are the primary targets in proteins.26    
Due to the high affinity of platinum(II) compounds to sulfur, sulfur containing 
molecules are frequently applied as rescue agents in cancer therapy. According to the 
previous investigations, mixed-ligand adducts formation is possible because of reversible 
methionine binding during the reaction of cisplatin with 5'-GMP in the presence of L-
Methionine.28 According to the Kung et al., the addition of L-Methionine at the 
physiological concentration results in an increase of the rate of complex formation at the 
initial step of the reaction and different adduct formation for the reaction with 
carboplatin, cis-[Pt(NH3)2(HM)], and cis-[Pt(NH3)2(M)].28 Oxaliplatin reacts faster with 
5’-GMP, and, contrary to the ammine ligands of the other complexes, the DACH ligand 
cannot be released.28,30 Formation of the chelate is favored in the presence of equimolar 
amounts of 5'-GMP and L-Met and the displacement of L-Met by 5’-GMP cannot be 
observed.28 These results indicate the correlation with our observations that 5'-GMP 
displaces oxalate ligands very slowly. 
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Platinum connectivity with sulfur is generally favored when compared to nitrogen 
and oxygen because platinum is a low electro negativity element and has a low energy   
LUMO. To differentiate sulfur from nitrogen and oxygen, sulfur has a large atomic 
radius, higher polarizability, and lower electro negativity than nitrogen and oxygen. 
Sulfur is also a soft base when compared to nitrogen and oxygen. According to HSAB 
theory, soft Lewis acids react faster and form stronger bonds with soft bases. Therefore, 
platinum connectivity with sulfur is more favored than with oxygen and nitrogen. 
In the current study, reactivities of [Pt(en)(Ox)] and [Pt(Me4en)(Ox)] with 5'-
GMP individually and in the presence of N-AcMet in 1:1 and 1:2 ratios at pH 4 are 
quantitatively studied using 1H  NMR spectroscopy. We used oxalates as leaving ligands 
because we wanted to see how the difference in the leaving ligand affected the reactivity 
of platinum complexes; the oxalate leaving ligand is utilized in the third generation 
anticancer drug oxaliplatin. We kept the pH at ~4 in order to keep the 5'-GMP phosphate 
group from completely deprotonating.  
The reactivity of [Pt(en)(Ox)] with 5'-GMP and N-AcMet is faster when 
compared with the bulkier complex [Pt(Me4 en)(Ox)]. Previously, it was shown that the 
[Pt(en)(D2O)]2+ reacted 13 times faster with 5'-GMP than [Pt(Me4 en)(D2O)]2+.18 The 
possible reasons for the slow reactivity of [Pt(Me4 en)(D2O)]2+ were due to several factors 
including steric bulk of the Me4en ligand, hydrogen bonding to the NH2 groups in [Pt( 
en)(D2O)]2, and possible trans effect differences due to the reaction trans to an NH2  vs. 
an N(CH3)2 group.  The current studies showed very slow reactivity of 5'-GMP with 
[Pt(Me4en)(Ox)]. After one week, two small downfield shifted H8 signals were observed, 
indicating the coordination of N7 residues with guanine. Thus, from these studies it can 
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be concluded the steric bulk of Me4en hindered the reactivity quickly when compared to 
en complex. 
A previous study found that  both platinum complexes [Pt(en)(D2O)2]+2 and 
[Pt(Me4en)(D2O)]+2 reacted faster with 5'-GMP. The possible explanation for its 
reactivity is due to the hydrogen bonding with a 5' phosphate and that the en ligand 
would not have any steric clashes with an incoming ligand.18 The reactivity is explained 
in two possible steps: the reaction of the diaqua complexes with the first guanine ligand, 
and the reaction of the mono product with the second guanine ligand. Although the 
reaction conditions utilized the favored formation of a mono-product, a mechanism to 
account for further reactions to bis-products was used.18 However, in the current study 
the reactions of  the platinum complexes [Pt(en)(Ox)] and [Pt(Me4en)(Ox)] with 5'-GMP  
result in the formation of bis-products with no intermediates. It indicates the second 5'-
GMP reacts faster than the first, since the first 5'-GMP has to break the oxalate chelate. 
The bis-products formed are [Pt(en(5'-GMP)2] and [Pt(Me4en)(5'-GMP)2]. 
The scheme of the possible reactions of [Pt(en)(Ox)] and [Pt(Me4en)(Ox)]  with  
5'-GMP is explained in Fig 28 and Fig 29 
 Figure 28. 
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Scheme of reactions of [Pt(en)(Ox)] with 5'-GMP
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reactions between [Pt(en)(D
addition to the mono-substituted
bis-products [Pt(en)(N-AcMet
are used only a bis substituted N
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4en)(Ox)] with 5'-GMP
eactivity with N-AcMet was favored more quickly at a 
[Pt(en)(N-AcMet-S)2], is formed. Previously, during
2O)2]+2   and N-AcMet, several products were observed
 product, an intermediate Pt(en)(N-AcMet
-S)2]  are also formed.18 When oxalates as 
-AcMet is formed with no intermediates.
 
1:2 
 the 
. In 
-S)(D2O)]+ and 
leaving ligands 
 
 Figure 30. Scheme of reactions of [Pt(en)(Ox)] with N
 Our previous study 
only one N-acetyl methionine residue to form S,
calculations suggested that a [Pt(Me
clashes regardless of the chiralities of the sulfur atoms or the relative orientations of the 
methionine residues. Also, the bulk prevented coordination of the amide nitrogen of an 
N-acetyl methionine residue.
[Pt(Me4 (en)Ox)] with N-
the easier replacement of oxalate ligands by methionine residues than by guanine 
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-AcMet
found that the [Pt(Me4en)(D2O)2]2+ complex 
 O chelates.18 Molecular mechanics 
4en)(Met-S)2]2+ complex would have severe steric 
18 The possible explanation for the faster reactivity of 
AcMet than with 5’-GMP in the current study could
 
 
reacted with 
 be due to 
 residues. The possible products formed when N
[Pt(Me4 en) (N-AcMet-S,
en)(Ox-o)(N-AcMet-S]+ 
Figure 31. Scheme of 
 Previously, by using capillary electrophoresis
spectrometry (CE-ESI-MS)
presence of the sulfur containing amino acid L
results from Kung et al, indicated a
Methionine for coordinating oxaliplatin and a favo
Consistent with the current study
when compared to the reactivity wi
methionine residues, and 
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-AcMet reacted with [Pt(Me
 O)]+ as well as the mono-substituted N-AcMet 
 
 
reactions of [Pt(Me4 (en)Ox)] with N-AcMet
-electospray ionization
, the binding behavior of oxaliplatin to 5'-GMP in the 
-methionine was investigated.
 competitive situation between 5'-GMP
red coordination of L-
, [Pt(en)(Ox)] reactivity with N-AcMet is faster 
th 5'-GMP. The oxalates are easily displa
product formation was observed quickly in hours rather than 
4 en)(Ox)] are 
product [Pt(Me4 
 
-mass 
27, 31  The 
 and L-
Methionine.  
ced by 
 days as in the case of reaction with 
[Pt(en)(Ox)] with N-AcMet and 
predominant products formed
N7)] and [Pt(en)(5'-GMP)
 
 
 
Figure 32. Scheme of reactions of [Pt(en)(Ox)] with N
When [Pt(Me4 en)(Ox)], N
in the H8 region of the spectrum was observed at 
(N-AcMet)( 5'-GMP)]+. 
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5'-GMP. Also, when competitive studies between
5'-GMP were investigated using 1H NMR
 were [Pt(en)(N-AcMet-S)2], [Pt(en)(N-AcMet
2.  
-AcMet and 5'
-AcMet, 5'-GMP were added together, 
~8.8 ppm corresponding
 
, The 
-S)(5'-GMP-
 
-GMP 
a new resonance 
  to [Pt(Me4en) 
 Figure 33. Scheme of reactions of [Pt(Me
When [Pt(Me4en)(Ox)] reacted with
products formed were [Pt(Me
GMP)]+. 
It was found that the oxalate leaving ligand slowed the reactivity more with 
GMP when compared to N
AcMet was added simultaneously to the mixture of platinum complex and 
 
48 
 
 
4en)(Ox)] with N-AcMet and 5'
 N-AcMet and 5'-GMP the predictable 
4 en)(Ox)(N-AcMet-S)]+ and [Pt(Me4en) (N
-AcMet. The reaction rate with 5'-GMP was faster when N
-GMP 
-AcMet)( 5'-
5'-
-
5'-GMP. This 
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result suggests that the N-AcMet reacts first to break the oxalate chelate, then the 5'-GMP 
displaces the unidentate oxalate ligand. 
In summary, we have utilized a 1H NMR spectroscopy to study the reactivity of 
platinum(II) diamine complexes [utilizing [Pt(en)(Ox)] as a non bulky complex and 
[Pt(Me4 en)(Ox)] as a bulky complex] with 5'-GMP and N-AcMet individually and 
competitively. The reactivity of [Pt(en)(Ox)] and [Pt(Me4 en)(Ox)] with 5'-GMP resulted 
in the bis-products with two substituted 5'-GMPs. The reactivity of [Pt(Me4 en)(Ox)] with 
5'-GMP was very slow comparatively with [Pt(en)(Ox)]. Bis-products such as [Pt(en)(N-
AcMet-S)2] are predominantly formed when [Pt(en)(Ox)] reacts with N-AcMet. When 
[Pt(Me4 en)(Ox)] reacts with N-AcMet two products are possible: one is [Pt(Me4 en) (N-
AcMet-S, O)]+,  the other is [Pt(Me4 en)(Ox-o)(N-AcMet-S]+. When competition studies 
of [Pt(en)(Ox)] with 5'-GMP and N-AcMet were conducted, the possible products formed 
were [Pt(en)(N-AcMet-S)(5'-GMP-N7)] and [Pt(en)(5'-GMP)2]. Reactivity of 
[Pt(Me4en)(Ox)] with N-AcMet and 5'-GMP resulted in [Pt(Me4en )(N-AcMet-S)( 5'-
GMP)]. The significant formation of [Pt(en)(N-AcMet-S)(5'-GMP-N7)] and[Pt(Me4en 
)(N-AcMet-S)( 5'-GMP)] product indicates that  N-AcMet reacts first to break the oxalate 
chelate then the 5'-GMP displaces the unidentate oxalate ligand; 
 Future studies will focus on the product of the reaction at different pH levels and 
time differences. Focus on studying the reactivity of platinum (II) complexes with 
oxalates as leaving ligands at pH-7 is important as there is less chance of dimerization 
reactions. Study of the reactivity of platinum(II) complexes with other amino acids like 
histidine and cysteine will also be pursued. 
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